Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Entrada Therapeutics (TRDA) Leases (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Leases data on record, last reported at $60.5 million in Q4 2025.

  • For Q4 2025, Leases fell 15.0% year-over-year to $60.5 million; the TTM value through Dec 2025 reached $60.5 million, down 15.0%, while the annual FY2025 figure was $60.5 million, 15.0% down from the prior year.
  • Leases reached $60.5 million in Q4 2025 per TRDA's latest filing, down from $62.1 million in the prior quarter.
  • Across five years, Leases topped out at $88.3 million in Q2 2023 and bottomed at $14.2 million in Q1 2023.
  • Average Leases over 4 years is $58.7 million, with a median of $67.1 million recorded in 2025.
  • Peak YoY movement for Leases: tumbled 54.64% in 2023, then soared 454.21% in 2024.
  • A 4-year view of Leases shows it stood at $25.3 million in 2022, then skyrocketed by 221.59% to $81.5 million in 2023, then dropped by 12.73% to $71.1 million in 2024, then fell by 15.0% to $60.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $60.5 million in Q4 2025, $62.1 million in Q3 2025, and $65.7 million in Q2 2025.